SCHEMBL404204

SCHEMBL404204

Cc1ccc2c(c1)nc(N1CCN(C(=O)OC(C)(C)C)CC1)c1nnnn12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.55
TP53 P04637 2/20 0.54
KDM4E B2RXH2 5/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
GAA P10253 1/20 0.49
POLB P06746 1/20 0.48
USP2 O75604 3/20 0.47
MAPK1 P28482 3/20 0.47
HSD17B10 Q99714 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HTT P42858 2/20 0.47
ALOX15 P16050 1/20 0.47
HBB P68871 1/20 0.46
TSHR P16473 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HPGD P15428 2/20 0.44
GBA1 P04062 1/20 0.42
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405395 0.92 TP53 (0.65) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL462741 0.88 POLB (0.50) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL405244 0.85 USP2 (0.47) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL12225042 0.83 TP53 (0.48) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL12225246 0.82 TP53 (0.49) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL463630 0.82 POLB (0.57) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL462613 0.82 USP2 (0.44) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL462854 0.81 USP2 (0.43) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL2463143 0.81 TP53 (0.48) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL12225247 0.81 TP53 (0.43) MAPTTP53KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 MAPT 2336/4885TP53 3565/4885KDM4E 1897/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 MAPT 2336/4885TP53 3565/4885KDM4E 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.